首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Impact of perioperative probiotic treatment for surgical site infections in patients with colorectal cancer
【2h】

Impact of perioperative probiotic treatment for surgical site infections in patients with colorectal cancer

机译:围手术期益生菌治疗对结直肠癌患者手术部位感染的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of the present study was to estimate the effect of the perioperative administration of probiotics in patients undergoing colorectal cancer (CRC) surgery. The study focused on a total of 156 consecutive surgeries carried out from among all the elective CRC surgeries performed between April 2009 and March 2013. The patients involved in surgeries undertaken between April 2009 and October 2011 were placed in the non-probiotic group (group A, 81 patients) and those involved in surgeries between November 2011 and March 2013 were placed in the probiotic group (group B, 75 patients). Postoperative infectious complications were recorded, and the immune responses and fecal microbiota were determined. A breakdown of infectious complications showed that 21 (13.5%) patients experienced superficial incisional surgical site infections (SSIs), of which 16 patients were from group A (19.8%), and five patients from group B (6.7%) (P=0.016). The ImmuKnow® adenosine triphosphate values peaked on the first postoperative day (POD) in both groups. In group A, the ImmuKnow value of the first POD was increased significantly compared with the preoperative value (P=0.022). In group B, the value of the first POD did not increase compared with the preoperative value (P=0.28). In conclusion, probiotic treatment can reduce superficial incisional SSIs in patients undergoing CRC surgery. Perioperative probiotic treatment can enhance immune responses and improve the intestinal microbial environment.
机译:本研究的目的是评估围手术期施用益生菌对结直肠癌(CRC)手术患者的效果。该研究的重点是从2009年4月至2013年3月进行的所有选择性CRC手术中总共进行了156例连续手术。2009年4月至2011年10月进行的手术患者被分为非益生菌组(A组) ,有81名患者)以及2011年11月至2013年3月之间参与手术的患者被纳入了益生菌组(B组,75名患者)。记录术后感染并发症,并确定免疫反应和粪便微生物群。感染并发症的细分显示,有21名(13.5%)的患者经历了浅表切口手术位点感染(SSI),其中A组16例(19.8%),B组5例(6.7%)(P = 0.016) )。两组术后第一天(POD)的ImmuKnow®三磷酸腺苷值均达到峰值。与手术前的值相比,A组的第一个POD的ImmuKnow值显着增加(P = 0.022)。在B组中,与手术前相比,第一个POD的值没有增加(P = 0.28)。总之,益生菌治疗可以减少接受CRC手术的患者的浅表切开SSI。围手术期益生菌治疗可以增强免疫反应并改善肠道微生物环境。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号